Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced −Highlights Phase 2 data for ATH434 in Multiple System ...
Abstract: This article presents system-level considerations for developing a battery-less photovoltaic energy harvesting front-end for powering multiple self-sustainable Internet of Thing (IoT) nodes ...
Detailed price information for Alterity Therapeutics Limited (PRNAF) from The Globe and Mail including charting and trades.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...
1 Department of Ophthalmology, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country, Barakaldo, Spain 2 Department of Retina, Instituto ...
Multiple myeloma is a blood cancer characterized by high rates of relapse. Despite recent advances in treatment, a significant unmet need remains for additional, well–tolerated therapies—particularly ...
Abstract: In recent years, the rapid development of electric vehicles (EVs) has led to the continuous innovation of charging technology. EV wireless charging is safer and more convenient than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results